Table 1
Lineage-specific differentiation induced by media supplementation
| Medium | Media | Serum | Supplementation |
|---|---|---|---|
| Control | DMEM | FBS (10%) | 1% antibiotic/antimycotic |
| Adipogenic (AM) | DMEM | FBS (10%) | 0.5 mM isobutyl-methylxanthine (IBMX), 1 μM dexamethasone, 10 μM insulin, 200 μM indomethacin, 1% antibiotic/antimycotic |
| Osteogenic (OM/VD) | DMEM | FBS (10%) | 0.01μM 1,25-dihydroxyvitamin D3 *, 50 μM ascorbate-2-phosphate, 10 mM β-glycerophosphate, 1% antibiotic/antimycotic |
| Chondrogenic (CM) | DMEM | FBS (1%) | 6.25 μg/ml insulin, 10 ng/ml TGFβ1, 50 nM ascorbate-2-phosphate, 1% antibiotic/antimycotic |
| Myogenic (MM) | DMEM | FBS (10%), HS (5%) | 50 μM hydrocortisone, 1% antibiotic/antimycotic |
| Neurogenic (NM) | DMEM | none | 5–10 mM β-mercaptoethanol |
*
0.1 μM dexamethasone can be used as a replacement of 0.01 μM vitamin D.
0.1 μM dexamethasone can be used as a replacement of 0.01 μM vitamin D.